a) Ankylosing spondylitis and psoriasis: main target areas on

(a) Ankylosing spondylitis and psoriasis: main target areas on vertebral column and girdle joints (b) Crohn disease and ulcerative colitis: main target.
Source: Low back pain, Murtagh s General Practice, 6e. Citation: Murtagh J. Murtagh s General Practice, 6e; 2015 Available at: image=/data/books/1522/murtagh6e_ch38_010.png&sec= &BookID=1522&ChapterSecID= &imagename= Accessed: November 05, Copyright © 2017 McGraw-Hill Education. All rights reserved.

Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016

Ankylosing Spondylitis, Burlington Therapy

Axial psoriatic arthritis: An update for dermatologists - ScienceDirect

Your Ankylosing Spondylitis Treatment Journey: What to Expect

Pure tone audiogram for unilateral (left) sensorineural deafness - ppt download

Psoriatic Arthritis vs. Lupus: Signs, Causes, Treatment

Frontiers Joint together: The etiology and pathogenesis of ankylosing spondylitis

Understanding Ankylosing Spondylitis Rash: Causes, Symptoms, and Treatment

Frontiers Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis

Bimekizumab is a Dual Anti-human IL17A/IL-17F Inhibitor for Plaque Psoriasis Research - Immune System Research

Simplified representation of the main mediators of inflammation in

COSENTYX® - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada(1)